< Back to all clusters
[HEALTH] · Germany · 20 sources

started · updated

THC treatment cuts PTSD nightmares in Berlin Charité study

Researchers at Charité – Universitätsmedizin Berlin, led by Prof. Stefan Röpke, conducted a randomized, placebo‑controlled trial of the cannabis‑derived drug dronabinol (THC) in 171 patients with post‑traumatic stress disorder (PTSD) who suffered frequent nightmares. Participants received the medication for ten weeks. More than half of those treated with THC showed a clinically relevant reduction in nightmare intensity, and over one‑third reported that nightmares disappeared completely. The overall severity of PTSD symptoms did not change significantly, and side effects were mild (e.g., dizziness, headache, increased appetite). The findings were published in *Nature Medicine* and highlight a potential new option for a symptom that current antidepressants and blood‑pressure drugs fail to address, although no specific medication for trauma‑related nightmares is yet approved in Germany.

The study suggests that THC may dampen REM‑sleep dream activity by interacting with the body’s endocannabinoid system, thereby reducing nocturnal stress responses. If confirmed in larger trials, the approach could offer relief to many PTSD patients who experience severe sleep disruption and fear of going to bed.

Entities

Charité – Universitätsmedizin Berlin · Charité – Universitätsmedizin Berlin · Dronabinol · Germany · Nature Medicine · Nature Medicine · Post‑traumatic stress disorder (PTSD) · Prof. Stefan Röpke · Stefan Röpke · THC (tetrahydrocannabinol) · Tetrahydrocannabinol (THC) · dronabinol (THC)

Claims

What the coverage asserts, and how many sources carry each claim.

Sources

15 days ago
16 days ago
16 days ago
16 days ago
16 days ago